In Vivo and In Vitro impact of carbohydrate variation on human follicle-stimulating hormone function

George R. Bousfield, Jeffrey V. May, John S Davis, James A. Dias, T. Rajendra Kumar

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Human follicle-stimulating hormone (FSH) exhibits both macro- and microheterogeneity in its carbohydrate moieties. Macroheterogeneity results in three physiologically relevant FSHβ subunit variants, two that possess a single N-linked glycan at either one of the two βL1 loop glycosylation sites or one with both glycans. Microheterogeneity is characterized by 80 to over 100 unique oligosaccharide structures attached to each of the 3 to 4 occupied N-glycosylation sites. With respect to its receptor, partially glycosylated (hypo-glycosylated) FSH variants exhibit higher association rates, greater apparent affinity, and greater occupancy than fully glycosylated FSH. Higher receptor binding-activity is reflected by greater in vitro bioactivity and, in some cases, greater in vivo bioactivity. Partially glycosylated pituitary FSH shows an age-related decline in abundance that may be associated with decreased fertility. In this review, we describe an integrated approach involving genetic models, in vitro signaling studies, FSH biochemistry, relevance of physiological changes in FSH glycoform abundance, and characterize the impact of FSH macroheterogeneity on fertility and reproductive aging. We will also address the controversy with regard to claims of a direct action of FSH in mediating bone loss especially at the peri- and postmenopausal stages.

Original languageEnglish (US)
Article number216
JournalFrontiers in Endocrinology
Volume9
Issue numberMAY
DOIs
StatePublished - May 9 2018

Fingerprint

Human Follicle Stimulating Hormone
Follicle Stimulating Hormone
Carbohydrates
Glycosylation
Polysaccharides
Fertility
Pituitary Hormones
In Vitro Techniques
Genetic Models
Oligosaccharides
Biochemistry
Bone and Bones

Keywords

  • Bone
  • Female Infertility
  • Follicle-stimulating hormone
  • N-glycosylation
  • Pituitary

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

In Vivo and In Vitro impact of carbohydrate variation on human follicle-stimulating hormone function. / Bousfield, George R.; May, Jeffrey V.; Davis, John S; Dias, James A.; Kumar, T. Rajendra.

In: Frontiers in Endocrinology, Vol. 9, No. MAY, 216, 09.05.2018.

Research output: Contribution to journalReview article

Bousfield, George R. ; May, Jeffrey V. ; Davis, John S ; Dias, James A. ; Kumar, T. Rajendra. / In Vivo and In Vitro impact of carbohydrate variation on human follicle-stimulating hormone function. In: Frontiers in Endocrinology. 2018 ; Vol. 9, No. MAY.
@article{657cad39ed39457ca5c5b6088b397cb8,
title = "In Vivo and In Vitro impact of carbohydrate variation on human follicle-stimulating hormone function",
abstract = "Human follicle-stimulating hormone (FSH) exhibits both macro- and microheterogeneity in its carbohydrate moieties. Macroheterogeneity results in three physiologically relevant FSHβ subunit variants, two that possess a single N-linked glycan at either one of the two βL1 loop glycosylation sites or one with both glycans. Microheterogeneity is characterized by 80 to over 100 unique oligosaccharide structures attached to each of the 3 to 4 occupied N-glycosylation sites. With respect to its receptor, partially glycosylated (hypo-glycosylated) FSH variants exhibit higher association rates, greater apparent affinity, and greater occupancy than fully glycosylated FSH. Higher receptor binding-activity is reflected by greater in vitro bioactivity and, in some cases, greater in vivo bioactivity. Partially glycosylated pituitary FSH shows an age-related decline in abundance that may be associated with decreased fertility. In this review, we describe an integrated approach involving genetic models, in vitro signaling studies, FSH biochemistry, relevance of physiological changes in FSH glycoform abundance, and characterize the impact of FSH macroheterogeneity on fertility and reproductive aging. We will also address the controversy with regard to claims of a direct action of FSH in mediating bone loss especially at the peri- and postmenopausal stages.",
keywords = "Bone, Female Infertility, Follicle-stimulating hormone, N-glycosylation, Pituitary",
author = "Bousfield, {George R.} and May, {Jeffrey V.} and Davis, {John S} and Dias, {James A.} and Kumar, {T. Rajendra}",
year = "2018",
month = "5",
day = "9",
doi = "10.3389/fendo.2018.00216",
language = "English (US)",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - In Vivo and In Vitro impact of carbohydrate variation on human follicle-stimulating hormone function

AU - Bousfield, George R.

AU - May, Jeffrey V.

AU - Davis, John S

AU - Dias, James A.

AU - Kumar, T. Rajendra

PY - 2018/5/9

Y1 - 2018/5/9

N2 - Human follicle-stimulating hormone (FSH) exhibits both macro- and microheterogeneity in its carbohydrate moieties. Macroheterogeneity results in three physiologically relevant FSHβ subunit variants, two that possess a single N-linked glycan at either one of the two βL1 loop glycosylation sites or one with both glycans. Microheterogeneity is characterized by 80 to over 100 unique oligosaccharide structures attached to each of the 3 to 4 occupied N-glycosylation sites. With respect to its receptor, partially glycosylated (hypo-glycosylated) FSH variants exhibit higher association rates, greater apparent affinity, and greater occupancy than fully glycosylated FSH. Higher receptor binding-activity is reflected by greater in vitro bioactivity and, in some cases, greater in vivo bioactivity. Partially glycosylated pituitary FSH shows an age-related decline in abundance that may be associated with decreased fertility. In this review, we describe an integrated approach involving genetic models, in vitro signaling studies, FSH biochemistry, relevance of physiological changes in FSH glycoform abundance, and characterize the impact of FSH macroheterogeneity on fertility and reproductive aging. We will also address the controversy with regard to claims of a direct action of FSH in mediating bone loss especially at the peri- and postmenopausal stages.

AB - Human follicle-stimulating hormone (FSH) exhibits both macro- and microheterogeneity in its carbohydrate moieties. Macroheterogeneity results in three physiologically relevant FSHβ subunit variants, two that possess a single N-linked glycan at either one of the two βL1 loop glycosylation sites or one with both glycans. Microheterogeneity is characterized by 80 to over 100 unique oligosaccharide structures attached to each of the 3 to 4 occupied N-glycosylation sites. With respect to its receptor, partially glycosylated (hypo-glycosylated) FSH variants exhibit higher association rates, greater apparent affinity, and greater occupancy than fully glycosylated FSH. Higher receptor binding-activity is reflected by greater in vitro bioactivity and, in some cases, greater in vivo bioactivity. Partially glycosylated pituitary FSH shows an age-related decline in abundance that may be associated with decreased fertility. In this review, we describe an integrated approach involving genetic models, in vitro signaling studies, FSH biochemistry, relevance of physiological changes in FSH glycoform abundance, and characterize the impact of FSH macroheterogeneity on fertility and reproductive aging. We will also address the controversy with regard to claims of a direct action of FSH in mediating bone loss especially at the peri- and postmenopausal stages.

KW - Bone

KW - Female Infertility

KW - Follicle-stimulating hormone

KW - N-glycosylation

KW - Pituitary

UR - http://www.scopus.com/inward/record.url?scp=85046696339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046696339&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00216

DO - 10.3389/fendo.2018.00216

M3 - Review article

C2 - 29867757

AN - SCOPUS:85046696339

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - MAY

M1 - 216

ER -